A Phase 1 interventional study of Transcranial Magnetic Stimulation and Cycloserine in Motor Activity, sponsored by University of Calgary. Completed at 1 site in Canada. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-09.
Sponsored by University of Calgary · Phase 1, Interventional, and Basic science
Among 32 studies in Motor Activity by University of Calgary — 12 open to participants now, 14 under way, none of them phase 3. Motor Activity · University of Calgary.
Among the 32 studies in Motor Activity by University of Calgary, this one is the 30th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 1, and was the 10th registered.
9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.
Browse Motor Activity studies →12 of the 32 studies in Motor Activity by University of Calgary are open now, in 1 country. Recruiting first, the newest first:
University of Calgary · Sites in Canada
University of Calgary · Sites in Canada
University of Calgary · Sites in Canada
University of Calgary · Sites in Canada
University of Calgary · Sites in Canada
By country, each count listing its studies:
Of the 1,201 Motor Activity studies recruiting now, 517 (43%) set no upper age limit and 535 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2018.
This study's enrollment of 12 is below the median of 60 across 8,388 interventional studies indexed under Motor Activity.
Median enrollment 39 across the 32 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Calgary is the lead sponsor of 703 studies on the registry; 196 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
1 of the studies in Motor Activity by University of Calgary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07626957University of CalgaryHamstring Strengthening in Hypermobile Conditions | 2027-05-01 |
Among the 32 studies in Motor Activity by University of Calgary, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Transcranial magnetic stimulation (rTMS) is an investigational and therapeutic modality that impacts the connection strength between neurons by delivering patterned energy. In response to this patterned energy neurons fire and adapt by changing their connection strengths. This change in connection strengths is believed to be the underlying mechanism whereby this intervention has therapeutic benefit for this intervention in conditions such as depression. The purpose of this study is to test a means of enhancing the effect of rTMS using a medication (cycloserine) that has been shown to augment and stabilize activity dependent neuronal changes. The investigators wish to use the motor system, where the associated muscle response to brain stimulation can be measured, to probe activity dependent changes in connection strength between neurons.
This randomized, placebo-controlled, crossover trial will enroll 12 healthy participants. In one arm of the study, participants will randomly receive either 100mg of d-cycloserine (DCS, an antibiotic) or a placebo capsule, and participants will receive the other intervention one week later.
As this is a cross-over study, participants will return 1 week later to repeat the second arm of the protocol and will repeat steps 2-10).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
Device: Transcranial Magnetic Stimulation · Drug: Cycloserine
Participants will ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
Device: Transcranial Magnetic Stimulation · Drug: Placebo Oral Tablet
Single-pulse transcranial magnetic stimulation and theta-burst stimulation
Cycloserine 100mg
Placebo capsule matched to cycloserine capsule
Motor Evoked Potential amplitude
Change in the (electrical) amplitude of muscle responses to stimulation of the motor cortex will be recorded from the first dorsal interosseous muscle of the hand.
Time frame: Baseline versus 90 minutes following theta-burst stimulation.
Motor Evoked Potential dose-response curve
Motor Evoked Potentials at stimulus intensities ranging from 100-150% resting motor threshold, presented in random order.
Time frame: Baseline versus 90 minutes following theta-burst stimulation.
Motor Evoked Potential dose-response curve
Motor Evoked Potentials at stimulus intensities ranging from 100-150% resting motor threshold, presented in random order.
Time frame: Baseline versus 16 hours following theta-burst stimulation.
Motor Evoked Potential Amplitude Time Course
Change in the (electrical) amplitude of muscle responses to stimulation of the motor cortex will be recorded from the first dorsal interosseous muscle of the hand.
Time frame: 90 minutes following theta-burst stimulation.
Safety outcomes
Adverse events will be tracked and recorded
Time frame: Through study completion, on average 2 weeks.
Side effects
Side effects will be tracked with the Toronto Side Effects Questionnaire
Time frame: Pre-stimulus and 16 hours post-stimulus for both arms of the crossover study.
Plan to share: Yes — There will be no sharing of individual participant data.
No publications or documents are linked to this record.
Ran from Aug 2018 to primary completion in Nov 2018, 3 months.
Of 73 non-industry phase 1 interventional studies under Motor Activity, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 3 months is below that.
Counting every sponsor, half of 75 studies reached it within 20 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cycloserine